All In Biotech

Drug Trial Radar · NCT06907875

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

Jul 7, 2027

Study completion Apr 30, 2032

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.

Conditions

  • Facioscapulohumeral Muscular Dystrophy

Interventions

  • EPI-321Biological

    EPI-321 IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of AEs and EPI-321 Related Adverse Reactions and Serious Adverse ReactionsTime frame: Baseline to up to 5 years.

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at University of California, Los Angeles

    Los Angeles, California

  • Rare Disease Research

    Atlanta, Georgia

  • Kennedy Krieger Institute, Center for Genetic Muscle Disorders

    Baltimore, Maryland

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Utah Program for Inherited Neuromuscular Disorders - University of Utah

    Salt Lake City, Utah

  • Royal Alfred Hospital

    Sydney, New South Wales, Australia

  • Pacific Clinical Research Network

    Auckland, New Zealand, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.